Janssen Pharmaceutica

Contact
janssenpharmaceutica.be
+3214602111

Janssen Pharmaceutica NV

Turnhoutseweg 30
2340 Beerse
Belgium
+3214602111
janssenpharmaceutica.be
Contact
Profile Products News
Contact

About Janssen Pharmaceutica

We are part of the world’s largest healthcare company, Johnson & Johnson, and enjoy an international reputation for pharmaceutical innovation and quality. For instance, EPREX™ , a breakthrough in the treatment of anaemia, has helped hundreds of thousands of patients and achieved sales of more than US$3 billion. And RISPERDAL™ , an innovative medicine for schizophrenia, won the first-ever International Prix Galien for outstanding pharmaceutical achievement.

Read more about Janssen Pharmaceutica
Facts about Janssen Pharmaceutica
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Janssen Pharmaceutica

Product portfolio

Show all

News about Janssen Pharmaceutica

Janssen Pharmaceutica

26-Jul-2024 | science

Measuring particle size distribution during the grinding process

A further step toward a stable measurement method for nanoparticles used in industry

Read news
Janssen Pharmaceutica

14-Jun-2022 | business & finance

Evotec enters a drug discovery collaboration with Janssen

Milestones up to approximately € 210 m per project

Read news
Janssen Pharmaceutica

28-May-2015 | science

New insights could result in changes to the therapeutic strategy to combat Alzheimer’s

​System developed for this research that could reduce a number of animal tests.

Read news
Janssen Pharmaceutica

20-May-2015 | research and development

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration

Proteros biostructures GmbH announced it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV triggering an ...

Read news
Janssen Pharmaceutica

27-Mar-2015 | business & finance

Philips enters into collaboration with Janssen to develop new handheld blood test

Royal Philips announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V.. The collaboration aims to develop a ...

Read news
Janssen Pharmaceutica

07-Nov-2012 | research and development

Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex

Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s ...

Read news
Janssen Pharmaceutica

28-Aug-2012 | research and development

Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis

Janssen Biologics announced it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc ( ...

Read news
Janssen Pharmaceutica

29-May-2012 | business & finance

Public-private collaboration launches to tackle antibiotic research

New €224m (£180m) funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing

Read news
Show more news about Janssen Pharmaceutica

Here you will find Janssen Pharmaceutica NV